Compare MD & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | SNDX |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1996 | 2014 |
| Metric | MD | SNDX |
|---|---|---|
| Price | $20.38 | $24.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $20.00 | ★ $84.17 |
| AVG Volume (30 Days) | 771.5K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | 11.56 |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $1,913,849,000.00 | $172,352,000.00 |
| Revenue This Year | $3.72 | $112.05 |
| Revenue Next Year | $2.62 | $51.24 |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $11.84 | $8.59 |
| 52 Week High | $24.99 | $25.44 |
| Indicator | MD | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 66.70 |
| Support Level | $16.08 | $19.46 |
| Resistance Level | $21.98 | $25.16 |
| Average True Range (ATR) | 0.70 | 1.09 |
| MACD | 0.12 | 0.09 |
| Stochastic Oscillator | 95.15 | 76.80 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.